Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6590MR)

This product GTTS-WQ6590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3721MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ3879MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ10522MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ11126MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ2477MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ5422MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ11MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ12324MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW